Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–716 of 716 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sequential Therapy Clear all
Terminated Phase 1 Interventional

A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors

NCT03967093
View directory record Official record
Conditions
Neoplasms
Interventions
BXQ-350
Drug
Lead sponsor
Bexion Pharmaceuticals, Inc.
Industry
Eligibility
1 Year to 30 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Results available

A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade

NCT03003676
View directory record Official record
Conditions
Advanced or Unresectable Melanoma Progressing After PD1 Blockade
Interventions
ONCOS-102, Cyclophosphamide, Pembrolizumab
Biological · Drug
Lead sponsor
Targovax Oy
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease

NCT01584440
View directory record Official record
Conditions
Agitation, Alzheimer's Disease
Interventions
AVP-923-20, Placebo, AVP-923-30
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
50 Years to 90 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
44
States / cities
Phoenix, Arizona • Sun City, Arizona • Fresno, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2021 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma

NCT01559935
View directory record Official record
Conditions
Multiple Myeloma
Interventions
carfilzomib, Dexamethasone, Clarithromycin, Lenalidomide
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 31, 2026, 10:35 PM EDT
Active, not recruiting Not applicable Interventional

Therapist-Directed VS Online Therapy for Insomnia Co-Occuring With Sleep Apnea

NCT03109210
View directory record Official record
Conditions
Insomnia, Primary, Sleep Apnea, Obstructive
Interventions
Online Cognitive Behavioral Therapy (OCBT), Therapist-directed Cognitive Behavioral Therapy (TCBT)
Behavioral
Lead sponsor
National Jewish Health
Other
Eligibility
21 Years and older
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
2
States / cities
Palo Alto, California • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Phase 1 Interventional

BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors

NCT04649385
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
BGB-15025, Tislelizumab, Carboplatin, Cisplatin, Pemetrexed, Oxaliplatin, Capecitabine, Paclitaxel, nab-paclitaxel
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
New York, New York • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 31, 2026, 10:35 PM EDT
Recruiting Phase 2 Interventional

Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

NCT07282912
View directory record Official record
Conditions
Foregut Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma, Pancreas Adenocarcinoma, Duodenal Adenocarcinoma, Ampullary Adenocarcinoma, Gallbladder Adenocarcinoma, Intra - and Extrahepatic Cholangiocarcinoma
Interventions
Sequential cytoreductive intervention, Signatera Genome ultra-sensitive ctDNA blood test
Procedure · Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer

NCT02499835
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Pembrolizumab, pTVG-HP Plasmid DNA Vaccine
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Not applicable Interventional Results available

Safety, Efficacy, and Dosing of Stereotactic Radiosurgery for Hepato-cellular Carc/Colo-rectal Liver Metastases

NCT01528878
View directory record Official record
Conditions
Liver Neoplasms, Colonic Neoplasms, Metastatic Cancer to Liver
Interventions
Stereotactic Radiosurgery using the CyberKnife System.
Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Phase 1 Interventional

Safety Study of Pritumumab in Brain Cancer

NCT04396717
View directory record Official record
Conditions
Malignant Primary Brain Tumors, Brain Metastases, Adult
Interventions
Pritumumab
Biological
Lead sponsor
Nascent Biotech
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Newport Beach, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 6, 2024 · Synced Oct 31, 2026, 10:35 PM EDT
Terminated Not applicable Interventional Results available

BOOST - Benefit of Frequent Optimization After Cardiac Resynchronization Therapy Device Replacement

NCT00929474
View directory record Official record
Conditions
Heart Failure
Interventions
QuickOpt - SJM CRT (Group 1), Control - SJM CRT (Group 2)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Aurora, Colorado • Hattiesburg, Mississippi
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 31, 2026, 10:35 PM EDT
Active, not recruiting Phase 2 Interventional

Sequential Therapy in Multiple Myeloma Guided by MRD Assessments

NCT05231629
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Dara-VRd intensification, Dara-R maintenance, AHCT intensification, Dara-R maintenance, AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance, AHCT intensification, Dara-R consolidation, Dara-R maintenance, Dara-VRd induction
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
10
States / cities
Birmingham, Alabama • Denver, Colorado • New York, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 31, 2026, 10:35 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer

NCT00702962
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Vorinostat, Carboplatin, Etoposide
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Oct 31, 2026, 10:35 PM EDT
Active, not recruiting Phase 1 Interventional

First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

NCT05489237
View directory record Official record
Conditions
Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases, Metastatic Cancer
Interventions
IDRX-42
Drug
Lead sponsor
IDRX, Inc., a wholly owned subsidiary of GSK, LLC
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Miami, Florida • Chicago, Illinois • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 31, 2026, 10:35 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Data2Action Oregon Project: Supporting Data-driven Decision-Making for Substance Use Services, Policy, and Overdose Prevention

NCT06852170
View directory record Official record
Conditions
Substance Abuse, Decision Making, Shared, Implementation Science, Decision Making, Organizations, Substance-related Disorders, Policy
Interventions
Co-Design Sessions (CDS), Data products
Other
Lead sponsor
Chestnut Health Systems
Other
Eligibility
18 Years and older
Enrollment
341 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Phase 1 Interventional

Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies

NCT01243359
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage I Renal Cell Cancer, Stage II Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sunitinib malate, bevacizumab, pharmacological study, laboratory biomarker analysis, fluorine F 18 fluorothymidine, positron emission tomography, computed tomography
Drug · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
2
States / cities
Baltimore, Maryland • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 31, 2026, 10:35 PM EDT
Terminated Phase 1Phase 2 Interventional

Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer

NCT00003086
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, CAF regimen, carboplatin, cisplatin, cyclophosphamide, doxorubicin hydrochloride, fluorouracil, ifosfamide, melphalan, paclitaxel, thiotepa, peripheral blood stem cell transplantation, samarium Sm 153 lexidronam pentasodium
Biological · Drug · Procedure + 1 more
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Phase 4 Interventional Results available

Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity

NCT04441996
View directory record Official record
Conditions
COVID-19
Interventions
Therapeutic plasma exchange (TPE), Standard of care
Biological · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 31, 2026, 10:35 PM EDT
Recruiting Phase 3 Interventional

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

NCT06256588
View directory record Official record
Conditions
Neoplasms, Head and Neck
Interventions
Dostarlimab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
36
States / cities
Jonesboro, Arkansas • Los Angeles, California • Solvang, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 31, 2026, 10:35 PM EDT
Active, not recruiting Phase 2 Interventional

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

NCT03607890
View directory record Official record
Conditions
Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors
Interventions
Nivolumab, Relatlimab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 31, 2026, 10:35 PM EDT